All-new Yunuverse cloud community capabilities, now standard on the Yunu platform, make it possible for over 1,000 on-demand specialty-trained radiologists, technologists, and study staff to be invited and instantly participate in any of the 4,000 in-flight imaging clinical trials running on the system today. Cancer centers may now extend the reach of trial programs to satellite sites and imaging centers, improving patient access to sophisticated oncology trials.
Read Press ReleaseAccording to Statista, China has the second largest pharmaceutical market in the world and plant-based medicines are very well accepted, which makes China a potential target market for Gb Sciences.
Read Press ReleaseAmplifyBio builds on the T-cell immunology expertise of its South San Francisco-based team, adding technology platforms and capabilities in single-cell analysis and product assessment in the context of a tumor microenvironment.
Read Press ReleaseNew multiyear collaboration between Florence Healthcare and IQVIA to ensure research sites participating in IQVIA studies have access to best-in-class site enablement technology to streamline operations and power remote connectivity.
Read Press ReleaseNTM-001 is an Investigational, Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for 24h Continuous Infusion. NTM-001 has the Potential to Deliver Opioid-Level Pain Relief Without Analgesic Gaps and Reduce or Eliminate the Need for Opioids. Phase 3 Efficacy and Safety Study is Comparing NTM-001 vs. Placebo, and Includes a Morphine Arm for Assay Sensitivity in Patients with Moderately Severe Pain After Bunionectomy Surgery. Results Expected Second Half 2023.
Read Press ReleasePresentation to include clinical data from a phase 2 study of Gruticibart (AB023), a factor XI-targeted antibody being developed for the treatment and prevention of thrombosis and inflammation
Read Press ReleaseENA-001, a New Chemical Entity (NCE) with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease designation for the Treatment of AoP by the FDA, with eligibility for a priority review voucher (PRV). The compound is also being developed by Enalare for the treatment of post-operative respiratory depression and community drug overdose.
Read Press ReleaseThe Funding Will Accelerate Development of an Intramuscular Formulation of ENA-001, a Novel Agnostic Respiratory Stimulant, for the Potential Treatment of Community Drug Overdose and as a Medical Countermeasure for Mass Casualty Events. The Funding Supports Development of an Intramuscular ENA-001 From Pre-Clinical Toxicology Through Filing for Approval in the United States
Read Press Release